Literature DB >> 31295221

Excess Cancer Cases and Medical Costs Due to Suboptimal Human Papillomavirus Vaccination Coverage in California.

Eleonore B Baughan, Erin M Keizur1, Christopher A Damico, Elizabeth Mayfield Arnold2, Jamie S Ko1, Jeffrey D Klausner1.   

Abstract

BACKGROUND: Human papillomavirus (HPV) vaccination coverage continues to be at low to moderate levels throughout the United States. HPV infection is linked to multiple types of cancers resulting in high economic and health burden. We aimed to estimate the excess number of cancer cases and associated medical costs due to current HPV vaccination coverage for a 20-year-old birth cohort in California.
METHODS: We estimated the lifetime number of cancer cases caused by vaccine-preventable strains of HPV for a cohort of 20 year-olds in California. We then estimated the excess number of cancer cases in that cohort which would occur due to 2017 HPV vaccination coverage compared with an optimal coverage of 99.5%. By multiplying those excess cases by the average cost of treatment, we determined the excess cost due to current HPV vaccination coverage.
RESULTS: With current vaccination coverage in California, the 20-year-old cohort is at risk for an excess 1352 cancer cases that could be prevented with a projected optimal vaccination coverage of 99.5%. The excess cost of treatment for those cancer cases would be US $52.2 million. Male oropharyngeal cancer accounts for the greatest projected cost burden US $21.3 million followed by cervical cancer US $16.1 million.
CONCLUSIONS: Increased HPV vaccination coverage in California is needed to reduce economic and health burdens associated with cancers caused by HPV infection.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31295221      PMCID: PMC6748638          DOI: 10.1097/OLQ.0000000000001016

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  16 in total

1.  Prevalence of HPV After Introduction of the Vaccination Program in the United States.

Authors:  Lauri E Markowitz; Gui Liu; Susan Hariri; Martin Steinau; Eileen F Dunne; Elizabeth R Unger
Journal:  Pediatrics       Date:  2016-02-22       Impact factor: 7.124

2.  US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines.

Authors:  Mona Saraiya; Elizabeth R Unger; Trevor D Thompson; Charles F Lynch; Brenda Y Hernandez; Christopher W Lyu; Martin Steinau; Meg Watson; Edward J Wilkinson; Claudia Hopenhayn; Glenn Copeland; Wendy Cozen; Edward S Peters; Youjie Huang; Maria Sibug Saber; Sean Altekruse; Marc T Goodman
Journal:  J Natl Cancer Inst       Date:  2015-04-29       Impact factor: 13.506

Review 3.  Ten Years of Human Papillomavirus Vaccination in the United States.

Authors:  Lauri E Markowitz; Julianne Gee; Harrell Chesson; Shannon Stokley
Journal:  Acad Pediatr       Date:  2018-03       Impact factor: 3.107

4.  The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model.

Authors:  Harrell W Chesson; Lauri E Markowitz; Susan Hariri; Donatus U Ekwueme; Mona Saraiya
Journal:  Hum Vaccin Immunother       Date:  2016-02-18       Impact factor: 3.452

5.  Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States.

Authors:  Harrell W Chesson; Donatus U Ekwueme; Mona Saraiya; Meg Watson; Douglas R Lowy; Lauri E Markowitz
Journal:  Vaccine       Date:  2012-08-04       Impact factor: 3.641

6.  Human Papillomavirus-Associated Cancers - United States, 2008-2012.

Authors:  Laura J Viens; S Jane Henley; Meg Watson; Lauri E Markowitz; Cheryll C Thomas; Trevor D Thompson; Hilda Razzaghi; Mona Saraiya
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-07-08       Impact factor: 17.586

7.  The economic burden of human papillomavirus-related precancers and cancers in Sweden.

Authors:  Ellinor Östensson; Maria Silfverschiöld; Lennart Greiff; Christine Asciutto; Johan Wennerberg; Marie-Louise Lydrup; Ulf Håkansson; Pär Sparén; Christer Borgfeldt
Journal:  PLoS One       Date:  2017-06-26       Impact factor: 3.240

8.  Vaccination Coverage Among Children Aged 19-35 Months - United States, 2016.

Authors:  Holly A Hill; Laurie D Elam-Evans; David Yankey; James A Singleton; Yoonjae Kang
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-11-03       Impact factor: 17.586

9.  National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2017.

Authors:  Tanja Y Walker; Laurie D Elam-Evans; David Yankey; Lauri E Markowitz; Charnetta L Williams; Sarah A Mbaeyi; Benjamin Fredua; Shannon Stokley
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-08-24       Impact factor: 17.586

10.  Cost-effectiveness of human papillomavirus vaccination in the United States.

Authors:  Harrell W Chesson; Donatus U Ekwueme; Mona Saraiya; Lauri E Markowitz
Journal:  Emerg Infect Dis       Date:  2008-02       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.